INMB240816C5000
- 4.10
- 0.000.00%
INmune Bio Newsroom
INmune Bio Second Quarter 2024 Earnings: US$0.51 Loss per Share (Vs US$0.36 Loss in 2Q 2023)
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
Earnings Flash (INMB) INMUNE BIO Reports Q2 Loss $-0.50, Vs. Street Est of $-0.63
INmune Bio | 10-Q: Quarterly report
Express News | INmune Bio Q2 Net Income USD -9.746 Million
Express News | INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
Express News | INmune Bio Q2 Basic EPS USD -0.5
Express News | INmune Bio Q2 Operating Expenses USD 9.865 Million
INmune Bio 2Q Loss/Shr 50c >INMB
INmune Bio Q2 2024 Earnings Preview
Buy Rating for Inmune Bio Supported by Promising XPro1595 Clinical Data in Neurodegenerative Disease Treatment
Express News | INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of Xpro™ on Proteins That Regulation Synapses in Alzheimer’s Patients
Express News | INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Inmune Bio's Clinical Advancements Secure Buy Rating From Analyst Jason McCarthy
Express News | INmune Highlights Publication Titled 'Proteomic and Phenotypic Characteristics of Memory-like Natural Killer Cells for Cancer Immunotherapy'
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer
INmune and Elevai Labs Amend Licensing Deal
Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21